Sartorius Stedim Biotech SA (DIM) fair value: what the stock is really worth
We calculate from audited financials what Sartorius Stedim Biotech SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Sartorius Stedim Biotech SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.
How to read this chart
60‑month range €144.21 – €538.09 · fair‑value band €24.06 – €71.27 · the €201.60 price screens above the €48.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
Show more
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Stock analysis
Sartorius Stedim Biotech SA (DIM) currently trades at €201.60, while our model-based Fair Value estimate is €48.88, implying the stock looks roughly 312.4% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €58.54 per share, and 0 of the 26 models we run sit above the €201.60 price.
Bear case: the Dividend Discount group reads lowest at €11.10, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €24.06 (bear) to €71.27 (bull), the price of €201.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Sartorius Stedim Biotech SA reported revenue of €3.0B in FY2025 versus €2.9B in FY2021, a compound +0.7%/yr. Reported net income was €266M in FY2025, compounding −10.5%/yr from FY2021.
Key figures
Market cap €19.6B · P/E ratio 72.8 · P/S ratio 6.51 · EPS (TTM) €2.77 · Dividend yield 0.4% · Net margin 9.0% · Return on equity 6.6% · Return on assets (EBIT) 12.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 10% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −76%, DIM screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€11.10 to €116.33). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €24.06Fair Value €48.88Bull €71.27
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€2.00 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.6%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−6% vs 8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 19%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+50.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.4%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (32 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Sartorius Stedim Biotech SA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks
Beats the industry median on 4/15 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−74% · Bottom 25%
Profitability
Return on equity (TTM)7% · Above median
Return on assets4% · Above median
Net margin (TTM)9% · Above median
Operating margin (TTM)20% · Top 25%
Growth and dividend
Revenue growth2% · Below median
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)72.8× · Priciest 25%
P/B5.06× · Priciest 25%
P/S (TTM)6.94× · Priciest 25%
P/FCF142.5× · Priciest 25%
EV/EBITDA28.1× · Priciest 25%
PEG1.61× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)12· sector 27
PAST (return on equity)26· sector 25
HEALTH (low debt)77· sector 96
DIVIDEND (yield)8· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sartorius Stedim Biotech SA Fair Value". https://www.fairvalue-calculator.com/stock/DIM
Frequently asked questions
Is Sartorius Stedim Biotech SA (DIM) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of €48.88 versus a price of €201.60, about −76% upside (overvalued).
What is the fair value of DIM?
Our model-based fair value for Sartorius Stedim Biotech SA is €48.88 (as of Sep 18, 2026), built from audited fundamentals. The current price: €201.60.
What is the quality score of DIM?
Sartorius Stedim Biotech SA has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sartorius Stedim Biotech SA (DIM)?
Our model-based price target is the fair value of €48.88 (as of Sep 18, 2026) from 26 valuation models. Cautious scenario €24.06, optimistic scenario €71.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Sartorius Stedim Biotech SA stock forecast for 2026?
Our models put fair value at €48.88, about −76% upside versus a price of €201.60 (overvalued). Cautious scenario €24.06, optimistic scenario €71.27. The calculation is refreshed regularly with new filings.
What is the revenue of Sartorius Stedim Biotech SA (DIM)?
Sartorius Stedim Biotech SA reported trailing-twelve-month revenue of about €3.0B (latest available figure, as of Sep 18, 2026).
Does Sartorius Stedim Biotech SA pay a dividend?
Sartorius Stedim Biotech SA currently shows a dividend yield of about 0.39% relative to its recent price (as of Sep 18, 2026).
What growth is priced into Sartorius Stedim Biotech SA (DIM)?
For today's price to be fair in a discounted-cash-flow model, Sartorius Stedim Biotech SA would have to grow free cash flow by +50.8 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.2 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of DIM use?
Our models discount Sartorius Stedim Biotech SA at 10.2 %: a base by market capitalisation (large), damped by beta 1.15, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sartorius Stedim Biotech SA that is +50.8 % per year a year over ten years, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Sartorius Stedim Biotech SA (DIM) delivered so far?
Over the past 5 years revenue at Sartorius Stedim Biotech SA grew +9.2 % a year. The price currently implies +50.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sartorius Stedim Biotech SA (DIM) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Sartorius Stedim Biotech SA (+50.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sartorius Stedim Biotech SA (DIM)?
The free-cash-flow yield on the price is 0.75 %: that much free cash flow Sartorius Stedim Biotech SA produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sartorius Stedim Biotech SA (DIM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sartorius Stedim Biotech SA it is €48.88 per share (as of Sep 18, 2026), against a price of €201.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sartorius Stedim Biotech SA stock overvalued or undervalued in 2026?
As of Sep 18, 2026, DIM trades above its calculated fair value: price €201.60, fair value €48.88, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DIM?
No. The price is what the market pays today (€201.60); the fair value is what the company's own numbers justify (€48.88). For Sartorius Stedim Biotech SA the two are €152.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sartorius Stedim Biotech SA worth?
The market values Sartorius Stedim Biotech SA at about €19.6B (market capitalisation, as of Sep 18, 2026). Per share that is €201.60; our models calculate a fair value of €48.88 per share.
What do the bullish and bearish scenarios say about DIM?
Our models span a range for Sartorius Stedim Biotech SA: cautious scenario €24.06, base €48.88, optimistic €71.27 per share (as of Sep 18, 2026, price €201.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DIM?
Sartorius Stedim Biotech SA trades at a price-to-earnings ratio of 72.8 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €48.88 is built from several models across several years. Other multiples: PEG 1.6, P/B 5.1, P/S 6.9, EV/EBITDA 28.1.
What is the PEG ratio of DIM?
The PEG ratio of Sartorius Stedim Biotech SA is 1.61 (P/E divided by earnings growth, as of Sep 18, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sartorius Stedim Biotech SA (DIM)?
Balance-sheet figures for Sartorius Stedim Biotech SA (as of Sep 18, 2026): return on equity 6.6%, debt of 0.46 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is DIM from its 52-week high?
Sartorius Stedim Biotech SA trades at €201.60, about 10% below its 52-week high of €223.09 and 34% above the low of €150.00 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of €48.88 is for.
Which stocks are comparable to Sartorius Stedim Biotech SA?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sartorius Stedim Biotech SA stock attractive at the current price?
The data as of Sep 18, 2026: price €201.60, calculated fair value €48.88 (−76%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DIM calculated?
We run Sartorius Stedim Biotech SA through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €48.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Sartorius Stedim Biotech SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sartorius Stedim Biotech SA (DIM)?
The closing price on Sep 21, 2026 was €201.60. Our model-based fair value is €48.88, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sartorius Stedim Biotech SA right now?
The price sits above even our optimistic bull case (€71.27). The favourable scenario is already priced in. The model range is unusually wide (€24.06 to €71.27). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Sartorius Stedim Biotech SA (DIM) come from?
Earnings per share at Sartorius Stedim Biotech SA grew +8.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.6 %, EBIT margin −2.3 %, tax rate +0.7 %, residual (interest, one-offs) −2.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sartorius Stedim Biotech SA
How large is the market capitalisation of Sartorius Stedim Biotech SA (DIM)?
The market capitalisation of Sartorius Stedim Biotech SA is €19.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sartorius Stedim Biotech SA (DIM)?
The price-to-sales ratio of Sartorius Stedim Biotech SA is 6.51 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sartorius Stedim Biotech SA (DIM)?
Earnings per share at Sartorius Stedim Biotech SA are €2.77 (price ÷ EPS = P/E 72.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sartorius Stedim Biotech SA (DIM)?
The dividend yield of Sartorius Stedim Biotech SA is 0.4% (payout 28.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sartorius Stedim Biotech SA (DIM)?
The net margin of Sartorius Stedim Biotech SA is 9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sartorius Stedim Biotech SA (DIM)?
The return on equity (ROE) of Sartorius Stedim Biotech SA is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sartorius Stedim Biotech SA (DIM)?
On an EBIT basis the return on assets of Sartorius Stedim Biotech SA is 12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sartorius Stedim Biotech SA (DIM)?
The operating margin of Sartorius Stedim Biotech SA is 19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sartorius Stedim Biotech SA (DIM)?
Revenue at Sartorius Stedim Biotech SA is growing +2.3% versus a year earlier (3y avg −5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sartorius Stedim Biotech SA (DIM)?
Earnings per share at Sartorius Stedim Biotech SA are growing +3.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sartorius Stedim Biotech SA (DIM) carry?
The net debt of Sartorius Stedim Biotech SA is €2.3B (fiscal year 2025, ≈ 16.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sartorius Stedim Biotech SA in the live analysis
One click puts Sartorius Stedim Biotech SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 18, 2026